TY - JOUR
T1 - The burden of prostate cancer in North Africa and Middle East, 1990–2019
T2 - Findings from the global burden of disease study
AU - GBD 2019 NAME Prostate Cancer Collaborators
AU - Abbasi-Kangevari, Mohsen
AU - Moghaddam, Sahar Saeedi
AU - Ghamari, Seyyed Hadi
AU - Azangou-Khyavy, Mohammadreza
AU - Malekpour, Mohammad Reza
AU - Rezaei, Negar
AU - Rezaei, Nazila
AU - Kolahi, Ali Asghar
AU - Amini, Erfan
AU - Mokdad, Ali H.
AU - Jamshidi, Hamidreza
AU - Naghavi, Mohsen
AU - Larijani, Bagher
AU - Farzadfar, Farshad
AU - Arif, Muhammad
AU - Khanali, Javad
AU - Rashidi, Mohammad Mahdi
AU - Ahmadi, Ali
AU - Ahmadi, Sepideh
AU - Gholamalizadeh, Maryam
AU - Haj-Mirzaian, Arvin
AU - Mafi, A. R.
AU - Nejadghaderi, Seyed Aria
AU - Azadnajafabad, Sina
AU - Maroufi, Seyed Farzad
AU - Mohammadi, Esmaeil
AU - Momtazmanesh, Sara
AU - Shobeiri, Parnian
AU - Abbasi, Behzad
AU - Akhavizadegan, Hamed
AU - Alimohamadi, Yousef
AU - Hafezi-Nejad, Nima
AU - Karimi, Amirali
AU - Nowroozi, Ali
AU - Malekzadeh, Reza
AU - Sepanlou, Sadaf G.
AU - Nasab, Entezar Mehrabi
AU - Shirkoohi, Reza
AU - Vakhshiteh, Faezeh
AU - Yazdanpanah, Jabbari Fereshteh
AU - Zahir, Mazyar
AU - Abidi, Hassan
AU - Zoladl, Mohammad
AU - Abu-Gharbieh, Eman
AU - Afzal, Muhammad Sohail
AU - Saqib, Nadeem
AU - Ahmad, Araz Ramazan
AU - Ahmad, Sajjad
AU - Mohammadian-Hafshejani, Abdollah
AU - Haque, Shafiul
N1 - Publisher Copyright:
Copyright © 2022 Abbasi-Kangevari, Saeedi Moghaddam, Ghamari, Azangou-Khyavy, Malekpour, Rezaei, Rezaei, Kolahi, GBD 2019 NAME Prostate Cancer Collaborators, Amini, Mokdad, Jamshidi, Naghavi, Larijani and Farzadfar.
PY - 2022/9/13
Y1 - 2022/9/13
N2 - Background: Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019. Methods: This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment. Results: The age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively. Conclusions: The PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years.
AB - Background: Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019. Methods: This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment. Results: The age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively. Conclusions: The PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years.
KW - cancer
KW - global burden of disease
KW - incidence
KW - mortality
KW - prostate-specific antigen
KW - prostatic neoplasms
UR - https://www.scopus.com/pages/publications/85139032777
U2 - 10.3389/fonc.2022.961086
DO - 10.3389/fonc.2022.961086
M3 - Article
AN - SCOPUS:85139032777
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 961086
ER -
SDG 3 Good Health and Well-being